Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000932471-24-000252
Filing Date
2024-11-04
Accepted
2024-11-04 10:57:36
Documents
1

Document Format Files

Seq Description Document Type Size
1 UnitedStates_13G__AllogeneTh.txt SC 13G 4047
  Complete submission text file 0000932471-24-000252.txt   5578
Mailing Address PO BOX 2600 V26 VALLEY FORGE PA 19482-2600
Business Address 100 VANGUARD BLVD MALVERN PA 19355 6106691000
VANGUARD GROUP INC (Filed by) CIK: 0000102909 (see all company filings)

EIN.: 231945930 | State of Incorp.: PA | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-90685 | Film No.: 241421364
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)